Format

Send to

Choose Destination
Endocrinol Metab Clin North Am. 2005 Mar;34(1):221-35.

Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon.

Author information

1
Divisions of Endocrinology and General Medicine, Diabetes Care Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7110, USA. jbuse@med.unc.edu

Abstract

There has been an explosion of interest in CVD and diabetes mellitus because of the epidemic nature of the diseases and their tight epidemiologic link. Clinical trials over the past decade have built substantial evidence for the role of lipid management, blood pressure control, and antiplatelet therapy in managing risk for CVD in patients who have diabetes mellitus. The many clinical trials underway will not only hone existing recommendations by establishing appropriate targets and techniques for lipid and blood pressure management, but also should demonstrate the role and most appropriate techniques for management of glycemia, flow-limiting coronary lesions, and obesity.

PMID:
15752929
DOI:
10.1016/j.ecl.2004.11.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center